Jazz Pharmaceuticals Enters into a 5-Year Research Collaboration Agreement with MD Anderson Cancer Center to Study Zanidatamab in Solid Tumors
Shots:
- As per the collaboration, MD Anderson will combine its translational medicine and clinical research expertise with Jazz's expanding oncology drug development capabilities in order to evaluate zanidatamab as a monotx. & in combination with other treatments for patients HER2-expressing solid tumors
- A joint advisory board involving MD Anderson and Jazz will be established to oversee the collaboration, which will fund multiple studies over the course of 5yrs. The research under the collaboration is anticipated to begin by YE 2023 or Q1'24
- Earlier, MD Anderson conducted a series of studies evaluating zanidatamab as a treatment for various tumor types incl. a P-II (HERIZON-BTC-01) clinical trial evaluating zanidatamab in HER2-amplified biliary tract cancer patients, the results for which were presented at ASCO 2023 depicting durable responses & ORR of 41%
Ref: PRNewswire | Image: Jazz Pharmaceuticals
Related News:- Jazz and Zymeworks Present P-IIb Trial (HERIZON-BTC-01) Results of Zanidatamab for HER2-Amplified Biliary Tract Cancers at ASCO 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
